Primary vs. pre-emptive anti-seizure medication prophylaxis in anti-CD19 CAR T-cell therapy.
Umberto PensatoFederica PondrelliChiara de PhilippisGian Maria AsioliAlessandra CrespiAlessandro BuizzaDaniele ManninaBeatrice CasadeiEnrico MaffiniLaura StraffiSimona MarcheselliPier Luigi ZinzaniFrancesca BonifaziMaria GuarinoStefania BramantiPublished in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2024)
Our data suggest that both primary and pre-emptive anti-seizure prophylaxis are safe and effective in anti-CD19 CAR T-cell recipients. Clinical rationale suggests a possible more favourable profile of primary prophylaxis, yet no definitive conclusion of superiority between the two ASM strategies can be drawn from our study.